Taiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease (TOReTO)

Study identification

• EU PAS number:
  EUPAS30087
• Study ID:
  30088
• Official title and acronym:
  Taiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease (TOReTO)
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study description:
  The primary objective is to understand the occurrence of COPD exacerbations in patients treated with LABA/LAMA in the routine clinical practice in Taiwan.The secondary objectives are to realize the clinical characteristics and prescription patterns for the COPD population in Taiwan.
• Study status:
  Planned

Research institutions and networks

Institutions

Linkou Chang Gung Memorial Hospital

Study timelines

Date when funding contract was signed

Planned: 31/07/2019

Study start date

Planned: 01/08/2019

Data analysis start date

Planned: 31/12/2019

Date of final study report

Planned: 29/02/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable